A 24-week randomized, double-blind, placebo-controlled trial in older adults found that high-dose nicotinamide mononucleotide supplementation produced sustained elevation of NAD⁺ levels rather than a transient spike. NAD⁺ availability declines with age and constrains mitochondrial energy output, DNA repair, and sirtuin-dependent signaling, making durable repletion a plausible lever for age-related functional decline. The trial's length and design address a central gap in prior NMN research, most of which ran for shorter periods at lower doses.
Key Points
- High-dose NMN sustained NAD⁺ elevation across 24 weeks in older adults
- Randomized, double-blind, placebo-controlled design in an aging population
- Duration and dose exceed most prior NMN supplementation trials
Longevity Analysis
NAD⁺ sits upstream of cellular repair capacity, mitochondrial output, and the enzymatic machinery that governs how cells respond to damage — which is why its age-related decline has become a focal point in intervention research. The distinction between a transient post-dose rise and a sustained plateau matters clinically: only the latter suggests the cofactor pool is genuinely restored rather than briefly saturated, and only sustained repletion is likely to influence downstream repair and energy metabolism. Blood NAD⁺ remains a surrogate marker, so the practical question for practitioners is whether consistent, long-horizon dosing translates into measurable functional change, tracked individually over time rather than inferred from biomarker movement alone.
Original published by Nature - npj Aging, by Masaki Igarashi.